Press Releases
Press Releases
More Press Releases
View Older Stories View Newer Stories-
Cupshe Unveils their For the Plot Party Collection in Collaboration with The Secret Lives of Mormon Wives Stars Jennifer Affleck, Demi Engemann, and Layla Taylor
-
Trivolve Tech and Quixy Launch Forensic Management System (FMS) on Cardano Mainnet
-
Liangzhu, where time speaks: Expats explore roots of Chinese civilization
-
Michael Green, Chief Strategist at Simplify Asset Management, joins WealthVest: The Weekly Bull & Bear Podcast
-
Crosby Brownlie Expands its Syracuse Location to Support Regional Growth
-
The 6th International Ancient Capitals Forum Kicks off in Luoyang, Focusing on the Sustainable Development of Ancient Capitals
-
/C O R R E C T I O N -- Express Wash Concepts/
-
Maple Financial Announces Strategic Equity Investment from Nesto Group via CMLS
-
Darkness to Light Expands National Scholarship Program Empowering Child Protection Leaders
-
Kelun-Biotech Presents Positive Results of Phase 3 Clinical Study OptiTROP-Breast02 for Sacituzumab Tirumotecan in Advanced HR+/HER2- Breast Cancer at 2025 ESMO
-
KEYTRUDA® (pembrolizumab) Plus Chemotherapy With or Without Bevacizumab Reduced Risk of Disease Progression or Death Versus Chemotherapy With or Without Bevacizumab in Certain Patients With Platinum-
-
ENHERTU® (fam-trastuzumab deruxtecan-nxki) reduced the risk of disease recurrence or death by 53% vs. T-DM1 in patients with high-risk HER2-positive early breast cancer following neoadjuvant therapy
-
Medome Launches New Medical Industry: Personal Health Intelligence TM - AI-Powered Personal Health Records to Usher In New Era of DIY Healthcare for ALL Americans
-
KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) Reduced Risk of Event-Free Survival Events by 60% and Risk of Death by 50% for Certain Patients with Muscle-Invasive Bladder Cancer W
-
ENHERTU® Followed by THP Before Surgery Resulted in a Pathologic Complete Response in 67% of Patients with High-Risk HER2 Positive Early-Stage Breast Cancer in DESTINY-Breast11 Phase 3 Trial
-
ENHERTU® Reduced the Risk of Disease Recurrence or Death by 53% Versus T-DM1 in Patients with High-Risk HER2 Positive Early Breast Cancer Following Neoadjuvant Therapy in DESTINY-Breast05 Phase 3 Tri
-
PADCEV™ Plus KEYTRUDA™, Given Before and After Surgery, Cuts the Risk of Recurrence, Progression or Death by 60% and the Risk of Death by 50% for Certain Patients with Bladder Cancer
-
ENHERTU® (fam-trastuzumab deruxtecan-nxki) followed by THP before surgery resulted in a pathologic complete response in 67% of patients with high-risk HER2-positive early-stage breast cancer in DESTI
-
BexBack Launches No KYC, 100x Leverage, and $50 Welcome Bonus for Easy Crypto Futures Trading!
-
Nasdaq Halts Platinum Analytics Cayman Limited
-
Nasdaq Halts Etoiles Capital Group Co., Ltd.
-
Nasdaq Halts Pitanium Limited
-
Vakiav Launches their First Window Smart Bird Feeder Designed for Effortless Setup and Instant Connection
-
Astra Bitcoin: Dr. Antoun Toubia Launches a Revolutionary Asset-Backed Ecosystem Built on Ethereum
-
Can Level 3 Interchange Rates Transform Your Margins Overnight?
-
Starting Small Checklist for Bulk Custom Phone Covers
-
China's Sichuan Extends Cultural Tourism Invitations at Global Landmarks
-
Global Sources Hong Kong Shows Phase II Officially Opens: AI Pavilion Debuts, Spotlighting Latest AI and Robotics Trends
-
Infrrd Announces the Official Launch of Ally: The First Agentic AI Workforce for Mortgage Auditing
-
Epomaker Unveils Magcore65 Lite: A Compact, Stable, and Durable Inductive Keyboard
-
Growing Up Spooky - Families Raised in America's Most Legendary Haunted Attractions
-
Looking for the Best Tax Advisors in Bangalore? Here’s Why Pyng Is the Right Choice
-
MorseLife Named a Fortune Media 2025 Best Workplace in Aging Services
-
DeFi crypto Mutuum Finance (MUTM) Onboards Over 17,300 Investors With 70% of Phase 6 Allocated
-
NuCana Presents Encouraging Data on NUC-7738 in Combination with PD-1 Inhibitors using Primary Patient-Derived Organoids and Autologous Tumor-Infiltrating Lymphocytes at the ESMO Congress 2025
-
University of Phoenix College of Social and Behavioral Sciences Leadership Publishes White Paper on Trauma-Informed Education
-
Reconstruction and Opportunities: The CDFG Consumer White Paper 2024-2025 is Released
-
Deciphera Presents 2-Year Efficacy and Safety Results from MOTION Phase 3 Study of ROMVIMZA™ (vimseltinib) in Patients with Tenosynovial Giant Cell Tumor (TGCT) at the European Society for Medical O
-
Andrew Left's Trial Begins -- Could Barry Honig Finally See Vindication?
-
Stop Believing Fake News: The Truth About MEXQuick and Scam Rumors
-
SurviveX Launches Tea-Tree-Infused Hydrogel Burn Dressings — Instant Cooling Relief with Professional-Grade Care
-
Masters Of Ring Entertainment Revolutionizes Professional Wrestling Industry with Triple Platform Launch
-
IDCXS Crypto Exchange Cuts Latency to Sub-Millisecond
-
Precede Biosciences Presents New ESMO 2025 Data Demonstrating Its Liquid Biopsy Platform’s Ability to Resolve Target Expression and Molecular Subtypes in Small Cell Lung Cancer
-
KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) Demonstrates Durable 5-Year Survival Benefit Versus Chemotherapy for Patients With Advanced Endometrial Carcinoma Following One Prior Platinum-Ba
-
Genmab Announces New Data Demonstrating Investigational Rinatabart Sesutecan (Rina-S®) Achieved Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Endometrial Cancer
-
Newfoundland and Labrador Victims and Survivors of Alcohol and Drug-Related Crashes Remembered at MADD Canada’s Annual Memorial Monument Ceremony
-
Nuvalent Presents Preliminary Data for Neladalkib in Advanced ALK-positive Solid Tumors Beyond NSCLC at ESMO 2025
-
Discover Our New Car Detailing Package
-
InvidiaTrade y TradingView se unen para ofrecer a los traders latinoamericanos una experiencia de analisis y ejecucion sin limites
